{"id":"arq-151-cream-0-05","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4303449","moleculeType":"Small molecule","molecularWeight":"552.44"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By selectively inhibiting JAK1, ARQ-151 reduces the activation of downstream signaling pathways such as STAT, which are involved in the production of pro-inflammatory cytokines and chemokines, thereby alleviating inflammation and associated symptoms.","oneSentence":"ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:29:15.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT04804605","phase":"PHASE3","title":"Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-02-25","conditions":"Atopic Dermatitis Eczema","enrollment":1220},{"nctId":"NCT04845620","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-04-07","conditions":"Atopic Dermatitis Eczema","enrollment":652},{"nctId":"NCT06998056","phase":"PHASE2","title":"Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2025-06-09","conditions":"Atopic Dermatitis (Eczema)","enrollment":101},{"nctId":"NCT04156191","phase":"PHASE1","title":"Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-23","conditions":"Atopic Dermatitis (Eczema)","enrollment":101},{"nctId":"NCT03916081","phase":"PHASE2","title":"Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-05-31","conditions":"Atopic Dermatitis","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARQ-151 cream 0.05%","genericName":"ARQ-151 cream 0.05%","companyName":"Arcutis Biotherapeutics, Inc.","companyId":"arcutis-biotherapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses. Used for Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}